Cannabis businesses—whether in cultivation, manufacturing, or retail—must comply with OSHA’s safety standards. This blog explains the importance of robust safety protocols, regulatory compliance, and proactive hazard management for long-term success.
Here, we bring you our top five recent news articles, covering National Hemp Day, certifications, and cannabis research studies.
The National Assembly in Panama approved a bill that would regulate the production, marketing, and export of hemp in the country.
This guide explores key certifications, benefits, and strategies to help position your cannabis company for success in 2025, while ensuring compliance, efficiency, and market access.
Two leading organizations, National Cannabis Roundtable and the US Cannabis Council are combining to create the new organization.
DEA Judge John Mulrooney II cancels upcoming cannabis rescheduling hearing, postponing cannabis reform.
It’s that time of year again—the Cannabis Science and Technology (CST) top 10 articles from the previous year. CST published a wide variety of content throughout 2024. Here is just a small snippet of some of the top articles that our readers enjoyed. See if any of your favorites made the list!
Here, we unpack key events and regulatory milestones of 2024, including rescheduling, OSHA compliance, banking, and innovations, plus we discuss the outlook for 2025.
Advancements in blockchain technology point toward an evolving landscape where transparency, security protocols, and regulatory compliance integrate into standard cannabis operations.
With the recent 2024 presidential election behind us, the future of cannabis still has many unknowns moving forward and questions still to be discussed. In this roundtable discussion with four knowledgeable industry leaders, we explore the nuanced political landscape of cannabis legalization and rescheduling in the context of the election, including state and federal policies and possible paths forward for testing standardization. Join us in the second part of a compilation of responses from Kim Anzarut, CQA, CP-FS, CEO of Allay Consulting; Susan Audino, PhD, founder of S.A. Audino & Associates, LLC; Zacariah Hildenbrand, PhD, research Professor at the University of Texas at El Paso; and David Vaillencourt, CEO of The GMP Collective.
With the recent 2024 presidential election behind us, the future of cannabis still has many unknowns moving forward and questions still to be discussed. In this roundtable discussion with four knowledgeable industry leaders, we explore the nuanced political landscape of cannabis legalization and rescheduling in the context of the election. We discuss what drives support or opposition from both sides of the aisle, the complexities of balancing state and federal priorities, and more. Join us in the first part of a compilation of responses from Kim Anzarut, CQA, CP-FS, CEO of Allay Consulting; Susan Audino, PhD, founder of S.A. Audino & Associates, LLC; Zacariah Hildenbrand, PhD, research Professor at the University of Texas at El Paso; and David Vaillencourt, CEO of The GMP Collective.
ASTM Standards D8557-24 and D8556-24, provide unified guidelines for GMP (Good Manufacturing Practices) and QMS (Quality Management Systems) in cannabis operations. These standards enhance compliance, product safety, and operational consistency across the industry for the benefit of operators, consumers, and other stakeholders in the industry.
The recent release of the Senate's draft for the 2024 Farm Bill could reshape how this versatile crop is cultivated, processed, and regulated.
This month’s GMP Collective webinar focused on how collaboration within the industry can lead to overall growth and success.
The U.S. Senate Committee on Agriculture, Nutrition, & Forestry has introduced the Rural Prosperity and Food Security Act, which will serve as the Senate’s draft for the 2024 Farm Bill.
The hemp products were seized from the ABC licensed locations for being out compliance with the state's new regulations.
The second part of this column will take a look at specific examples in the public domain of elemental contamination of cannabis consumer products, which shows that other elements are worthy of consideration and should be a part of the regulatory framework.
Inconsistent testing is a significant issue in the cannabis industry, contributing to fears about potency inflation and product safety. However, adopting cGMP compliance offers a clear solution by implementing standardized testing protocols, comprehensive batch testing, and rigorous third-party verification.
The new hemp regulations, limiting THC levels in products, took effect in September.
The ruling states that federal law does not block the ban on certain cannabinoid products in the state.
This report is the first one published since the state’s legal market began.
The temporary restraining order would prevent the enforcement of these regulations while the lawsuit is being litigated.
As we approach a pivotal election, the cannabis industry finds itself at a crossroads. If federal legalization passes, cannabis could be reclassified from a Schedule I to a Schedule III drug. This shift would remove many barriers for businesses and consumers, opening the door to broader acceptance and regulation. However, this potential change also stirs up concerns among those opposed to cannabis, who fear its legalization could lead to unchecked risks for public health and safety.
The bill would amend the definition of hemp to raise the threshold of delta-9 THC to 1% from 0.3%.
The Cannabinoid Safety and Regulation Act would establish a regulatory regime for products that contain hemp cannabinoids.
